Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics
- 1 January 1986
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 30 (2) , 253-255
- https://doi.org/10.1007/bf00614315
Abstract
The effect of a new alpha-glucosidase inhibitor (BAY m 1099), a 1-deoxynojirimycin derivative, was studied in 10 black patients with Type II diabetes mellitus. It produced significant lowering of blood glucose concentration after standardized maize porridge meals. No significant untoward effects were noted. BAY m 1099 appears to offer potential benefit in the management of Type II diabetics, and more extensive clinical investigation is warranted.This publication has 5 references indexed in Scilit:
- The effect of a 1-deoxynojirimycin derivative on post-prandial blood glucose and insulin levels in healthy black and white volunteersEuropean Journal of Clinical Pharmacology, 1985
- Inhibition of N-linked complex oligosaccharide formation by 1-deoxynojirimycin, an inhibitor of processing glucosidases.Journal of Biological Chemistry, 1982
- Glucosidase-Inhibitoren aus BazillenThe Science of Nature, 1979